Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2013

View Archived Issues

International trial of rhNGF begins in the treatment of neurotrophic keratitis

Roche presents potential predictivity of preclinical cancer models

177Lu-J-591 shows promising antitumor activity at the MTD of 70 mCi/m2

Shin Nippon Biomedical Laboratories and Kyoto University enter agreement

Mylan enters generic insulin agreement with Biocon

Antitumor activity demonstrated for TRAIL-inducing compound TIC-10

Dako launches nontoxic FISH assay for cancer diagnosis in U.S.

Third Rock Ventures launches new company with a focus on cancer immunotherapy

Emory University and Health Research patent new TAK1 inhibitors

Novartis presents final results of a phase II study of dovitinib in urothelial cancer

FDA grants orphan drug status to OSE-2101

GlaxoSmithKline presents novel Lp-PLA2 inhibitors

Nerviano Medical Sciences divulges new protein kinase inhibitors

Novel c-Kit inhibitors presented by AB Science

Researchers at Allergan synthesize new alpha-adrenoceptor agonists

Phase II results for linsitinib in mCRPC presented

Livalo OD tablets approved in Japan for hypercholesteremia

FDA advisory committee recommends approval of contrast agent Dotarem

FDA accepts Oralair BLA for review

Piromelatine shows promise in phase II insomnia trial

Verastem compounds target cancer stem cells

FDA approves Zortress in new indication

Scientists at Grunenthal prepare novel TRPV1 ligands

Lilly and QIAGEN to collaborate on companion diagnostics

FDA grants priority review to dolutegravir NDA

Phase II trial of Cogane in Parkinson's disease misses endpoints

FDA approves Argus II Retinal Prosthesis System for patients with advanced retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...